Molecular glue reaches cancer targets once out of range
Most drugs work by blocking a single protein. But a special class of molecules, called molecular glues, works differently. They stick two proteins together that wouldn’t normally interact, forcing one to be destroyed by the cell. New research shows this approach can now reach far more proteins than previously thought.
Molecular glues are small molecules that bring two proteins into proximity. By doing so, they can redirect the cell’s own protein disposal machinery to destroy a harmful protein. A well-studied class works through the protein CRBN, which is part of the ubiquitin-proteasome system, the cellular mechanism that tags and removes unwanted proteins. The researchers, publishing in Science, found that CRBN-based molecular glues can recruit the enzyme KAT2A independently of the usual recognition signal.
Normally, CRBN recognizes a specific tag on proteins marked for disposal, known as a degron. This new finding shows that KAT2A can be drawn in without such a tag, a mechanism the researchers call degron-independent recruitment. That substantially expands the landscape of proteins that CRBN-based drugs might target.
Implications for drug development
Many proteins that drive cancer growth have no obvious binding site for conventional drugs. Molecular glues offer an alternative: instead of blocking a protein, they cause it to be degraded. The discovery of degron-independent recruitment opens a new category of potentially targetable proteins, including those previously considered undruggable.
KAT2A plays a role in regulating gene activity across multiple cell types, including immune cells. Whether this pathway holds relevance for age-related conditions is speculative, but the mechanistic expansion is significant for future research directions in both oncology and aging biology.
Where the research stands
The findings come from cell and biochemical experiments. Clinical applications remain distant. The study is mechanistic in focus, aimed at better characterizing the capabilities of a promising drug class. Further optimization and safety testing will be required before any translation to patients is possible.
Want to research this yourself?
Search for example:
- molecular glue protein degradation
- CRBN ubiquitin ligase drug development
- targeted protein degradation cancer